Domestic Agent vs In-House China Team: Which Medical Device Registration Approach?
For foreign medical device manufacturers entering China, the decision to use a Domestic Agent (境内代理人, jìngnèi dàilǐrén) versus building an In-House China Team (在华团队, zài huá tuánduì) can determine whether your NMPA registration takes 12 months or 36 months. Under China’s Medical Device Registration Regulation (医疗器械注册管理办法, yīliáo qìxiè zhùcè guǎnlǐ bànfǎ), every foreign manufacturer must designate a domestic agent for registration filings — but the agent can be a third-party service provider or your own legal entity in China. This comparison analyzes both approaches across cost, speed, compliance risk, and long-term scalability.
Why Your China Device Registration Approach Matters More Than Ever
China’s National Medical Products Administration (NMPA) revised its registration pathway in 2024 to require direct liability from the domestic agent. Under the new provisions, the agent is jointly responsible for product safety, adverse event reporting, and post-market surveillance — meaning your choice is not just about filing paperwork. The wrong approach can lead to registration rejection, product recalls, or blacklisting.
Approximately 68% of foreign medical device companies entering China for the first time use a third-party domestic agent, while 22% establish a WFOE (外商独资企业, wàishāng dúzī qǐyè) to act as their own agent, and the remaining 10% operate through a joint venture or branch office — according to 2024 industry data from the China Medical Device Association. Yet nearly 41% of first-time registrants who used a third-party agent faced compliance gaps requiring re-filing, increasing their timeline by an average of 9 months and costing an additional ¥150,000–¥300,000 per product.
The choice between a domestic agent and an in-house China team is therefore a strategic decision that affects registration speed, operational risk, and market entry cost — typically ranging from ¥500,000 for Class II devices via agent to ¥3,000,000+ for Class III devices with a fully built in-house team.
Domestic Agent Approach: Pros, Cons, and Real Costs
A domestic agent is a China-registered entity that acts as your legal representative with the NMPA. This can be a specialized regulatory consultancy, a law firm with medical device practice, or a trading company that holds your registration certificates and manages communications with Chinese authorities.
Key Advantages of Using a Domestic Agent
Speed of setup. You can engage a qualified agent in 2–4 weeks without incorporating in China. The agent uses existing procedures and relationships with NMPA reviewers, potentially reducing registration review time by 25–40% compared to a new in-house team learning the system.
Lower initial capital commitment. Agent fees for Class II device registration typically range from ¥120,000 to ¥250,000 per product, versus ¥1,500,000+ to establish a WFOE and hire a regulatory team. There are no office lease, HR, or social insurance costs.
Regulatory specialization. Top-tier agents handle 50–200+ registrations annually. They know current NMPA reviewer preferences, testing lab requirements, and documentation standards. They can also manage post-market compliance including adverse event reporting (不良事件报告, bùliáng shìjiàn bàogào) and renewal deadlines.
Critical Disadvantages to Consider
Limited control over quality and timelines. You rely on the agent’s workflow and responsiveness. If the agent delays, your registration stalls. If the agent makes a documentation error, you bear the consequences. Over 30% of foreign companies report communication delays of 2–4 weeks per review cycle when using an offshore agent model.
No internal capability buildup. The agent retains all regulatory knowledge. When you need to register a second product line, you pay again. You cannot transfer that expertise to your own team.
Agent liability concentration. If your agent loses its NMPA qualification (e.g., due to its own violations), your registrations become orphaned. Re-registering through a new agent can take 6–12 months and cost ¥80,000–¥150,000 per product.
In-House China Team Approach: Building for the Long Term
An in-house China team means establishing a legal entity in China — typically a Wholly Foreign-Owned Enterprise (外商独资企业, wàishāng dúzī qǐyè or WFOE) — and hiring your own regulatory affairs (RA) professionals to manage NMPA registrations directly. This approach is favored by multinationals expecting to register 10 or more products within 3 years.
Key Advantages of an In-House China Team
Full control and accountability. Your RA team reports to your headquarters and follows your internal SOPs. Registration timelines, document quality, and compliance posture are directly manageable. Companies with in-house teams report 40–60% fewer re-filing incidents compared to agent-managed registrations.
Knowledge retention and scalability. Every registration builds institutional knowledge. Your team learns NMPA patterns, develops relationships with testing labs (e.g., CMDE (国家医疗器械技术审评中心, guójiā yīliáo qìxiè jìshù shěnpíng zhōngxīn)), and can manage 5–15 products simultaneously without incremental agency fees.
Long-term cost efficiency. For companies registering 5+ Class II products over 3 years, the in-house model becomes cheaper. The break-even point is typically 18–24 months after entity establishment. At 10+ products, the cost per registration drops to roughly 40% of the agent model.
Key Disadvantages and Challenges
High upfront investment. Establishing a WFOE in a major city like Shanghai or Beijing costs ¥200,000–¥400,000 in legal, registration, and initial office expenses. Hiring two experienced RA managers costs ¥500,000–¥800,000 per year in salary and social insurance. Total first-year cost: ¥1,500,000–¥2,500,000.
Slow startup timeline. Entity registration takes 2–4 months. Recruiting qualified RA staff takes another 2–4 months. The first registration submission typically happens 6–9 months after the decision to proceed — versus 1–2 months with an agent.
Headcount risk. If registration volumes fluctuate, you may need to hire or reduce staff. China’s labor laws make termination costly — typically ¥30,000–¥80,000 per employee in severance and legal costs.
Comparative Analysis: Agent vs In-House Team
| Factor | Domestic Agent | In-House China Team (WFOE) |
|---|---|---|
| Time to first submission | 1–2 months | 6–9 months |
| Cost for 1st Class II product | ¥120,000–¥250,000 | ¥1,500,000–¥2,500,000 (includes entity setup + 1 year team) |
| Cost for 5th Class II product (cumulative 3 years) | ¥600,000–¥1,250,000 | ¥2,500,000–¥4,000,000 |
| Cost for 10th Class II product (cumulative 5 years) | ¥1,200,000–¥2,500,000 | ¥4,000,000–¥6,500,000 |
| Break-even point vs agent (Class II) | N/A — always pay per product | 18–24 months or 5+ products |
| Regulatory control level | Moderate — agent controls workflow | High — direct management |
| Knowledge retention | None — agent retains all | Full — institutional knowledge grows |
| Post-market compliance support | Available via contract (extra fee) | Built into team responsibilities |
| Scalability for 10+ products | Expensive — each product costs ¥120,000–¥250,000 | Cost per product drops to ¥80,000–¥120,000 |
| Typical NMPA review time (Class II) | 8–14 months | 10–16 months (first product), 8–12 months (subsequent) |
| Best for | 1–3 products, testing the market | 5+ products, long-term commitment |
Decision Framework: Which Approach Fits Your Situation?
Use this framework to map your specific conditions to the optimal registration approach:
If you have 1–3 products and expect limited future pipeline expansion, choose a domestic agent. You avoid the six-figure upfront investment and can test market demand without organizational commitment. Ensure the agent has at least 5 years of device registration experience and can provide references from 3+ foreign clients.
If you have 4–8 products and plan to register them within 2 years, choose a domestic agent for the first 2 products while simultaneously incorporating a WFOE and recruiting an RA team. This hybrid approach lets you submit early registrations quickly while building long-term capability. Many successful foreign device companies use this phased model.
If you have 10+ products or expect ongoing new product registrations each year, choose an in-house team via WFOE. The upfront cost is justified by cost-per-product savings after product #5–7, plus you gain full control over compliance and institutional knowledge that no agent can replicate.
If you face time pressure (must register within 12 months), choose a domestic agent with a track record of expedited submissions. Only an agent with existing NMPA reviewer relationships and ready-to-use documentation templates can realistically meet aggressive timelines.
3 Critical Pitfalls in Registration Approach Selection
NEXT STEPS: 3 Recommendations to Move Forward
Based on this analysis, here are three concrete actions depending on where you are now:
- Download our free China Medical Device Registration Readiness Checklist — covers NMPA classification, testing requirements, and documentation gaps for Class II and III devices. Get the checklist →
- Evaluate your product portfolio against the break-even calculator — if you have 5+ products and plan China expansion, explore our guide to establishing a medical device WFOE. Read the WFOE setup guide →
- Book a 30-minute registration pathway consultation — our regulatory advisors assess your product risk class, desired timeline, and pipeline to recommend agent vs in-house approach, including estimated costs and timelines. Schedule your consultation →
— China Gateway 360 —
Remote China market entry support, built around execution.
